Trials / Completed
CompletedNCT03587805
Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
An Open-label, Single-arm, Multi-centre, Long-term Extension Trial to Evaluate the Safety and Efficacy of Tralokinumab in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Clinical Trials
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,672 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this extension trial is to evaluate the long-term safety of tralokinumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tralokinumab | Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection. |
Timeline
- Start date
- 2018-03-18
- Primary completion
- 2024-07-03
- Completion
- 2024-07-03
- First posted
- 2018-07-16
- Last updated
- 2025-03-11
- Results posted
- 2025-01-16
Locations
309 sites across 11 countries: United States, Belgium, Canada, Czechia, France, Germany, Italy, Japan, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03587805. Inclusion in this directory is not an endorsement.